Almost 2 years after its inauguration, the FAST TRACK Evaluation Service is unveiling a new brand identity.
Officially launched by the CATALIS Network in September 2022, the FAST TRACK Evaluation Service aims to authorize clinical trials in ≤ 8 weeks.
We are pleased to announce that, to date, the service has enabled the authorization of 37 clinical trials conducted by 9 major pharmaceutical companies in 14 participating Health and Social Service Institutions (établissements de santé et de services sociaux (ESSS)), representing a total of 67 FAST TRACK authorizations in record time.
Indeed, the FAST TRACK Evaluation Service enabled the ESSS to authorize these clinical trials in a median of 9 weeks, and sponsors to activate them in a median of 13 weeks, a reduction of nearly 75% of the standard authorization times.
Many of the participating ESSS were among the first activated sites in the world, raising the profile of Quebec’s capabilities and expertise internationally and speeding up the recruitment of patients from the province.
We would like to thank AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, GSK, Novartis, Pfizer, Roche, Sanofi and our participating ESSS, as well as all members of our Network, for contributing to the great success of this service. Thanks to your commitment and trust, we have been able to demonstrate that it is possible to optimize administrative processes to accelerate the development of innovative treatments for the benefit of patients.
Should you want more information about the FAST TRACK Evaluation Service, please write to us at: info@catalisquebec.com.
